Back to News
Market Impact: 0.4
AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up
Source: Nasdaq
Healthcare & BiotechCorporate Earnings
AstraZeneca reported positive Phase 3 results for sonesitatug vedotin (Sone-V), saying it significantly improved overall survival in patients with CLDN18.2-positive advanced gastric, gastroesophageal junction, and oesophageal adenocarcinoma cancers. The provided article text contains no effect size, trial details, or further information.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
AZN0.85
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Why is PagSeguro Digital stock plummeting 30% today?
- China industrial profits post strongest growth in three months, rising 14.4%
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Celestica stock surges 10% after earnings beat as AI demand boosts 2027 outlook
- JetBlue posts bigger loss on fuel costs, but CEO says margins improving